Payment overview · 2025
General Payments
$73,137.19
150 reported records · 29 companies
Healthcare provider profile · identity verified
Arthur C Lee, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · GAINESVILLE, FL · NPI 1063447977
Verified facts
What the public records show
CMS Open Payments records show Arthur C Lee, MD received $73,137.19 in general payments during 2025 across 150 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Brilinta by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14,382.30 | 19.7% | 8 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $13,655.15 | 18.7% | 5 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $12,943.12 | 17.7% | 30 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $12,530.00 | 17.1% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $10,798.09 | 14.8% | 14 | 2025 |
| Cook Incorporated | Unresolved — no canonical attribution shown | $3,425.00 | 4.7% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $1,847.78 | 2.5% | 7 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $1,051.12 | 1.4% | 28 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $669.69 | 0.9% | 7 | 2025 |
| CMS Imaging, Inc. | Unresolved — no canonical attribution shown | $272.13 | 0.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $232.23 | 0.3% | 10 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $169.34 | 0.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$155.63 | 0.2% | 4 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $150.32 | 0.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $122.00 | 0.2% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $117.92 | 0.2% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $110.98 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $108.46 | 0.1% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $67.21 | 0.1% | 3 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $56.86 | 0.1% | 2 | 2025 |
| Inquis Medical, Inc. | Unresolved — no canonical attribution shown | $56.43 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $44.86 | 0.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.16 | 0.1% | 2 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $34.62 | 0.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.96 | 0.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.53 | 0.0% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $19.52 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.85 | 0.0% | 1 | 2025 |
| Neuros Medical, Inc. | Unresolved — no canonical attribution shown | $13.93 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,712.00 | 19 |
| Consulting Fee | $21,365.39 | 3 |
| Food and Beverage | $5,863.48 | 120 |
| Travel and Lodging | $4,736.32 | 7 |
| Long term medical supply or device loan | $460.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $16,662.30 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $10,798.09 | 14 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $10,727.43 | 27 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $2,026.66 | 8 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $1,847.78 | 7 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $1,755.69 | 2 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $490.81 | 6 | 2025 |
Source payment records
|
|||||
| VenaCure 1470 Pro Normalized: venacure 1470 pro |
Device | AngioDynamics, Inc. | $460.00 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $430.15 | 4 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $341.60 | 5 | 2025 |
Source payment records
|
|||||
| ICAST COVERED STENT SYSTEM, 6MMX22MMX120CM Normalized: icast covered stent system 6mmx22mmx120cm |
Device | Cook Medical LLC | $247.24 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $232.23 | 10 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $169.34 | 2 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $150.32 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $150.32 | 1 | 2025 |
Source payment records
|
|||||
| ROSEN Normalized: rosen |
Device | Cook Medical LLC | $136.08 | 6 | 2025 |
Source payment records
|
|||||
| COOK Normalized: cook |
Device | Cook Medical LLC | $135.49 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $134.21 | 3 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM Septal Occluder Normalized: gore cardioform septal occluder |
Device | W. L. Gore & Associates, Inc. | $117.92 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $110.98 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $108.46 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $97.70 | 4 | 2025 |
Source payment records
|
|||||
| ZILVER VENA Normalized: zilver vena |
Device | Cook Medical LLC | $91.14 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $67.21 | 3 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $56.86 | 2 | 2025 |
Source payment records
|
|||||
| Aventus Normalized: aventus |
Device | Inquis Medical, Inc. | $56.43 | 1 | 2025 |
Source payment records
|
|||||
| TORNADO Normalized: tornado |
Device | Cook Medical LLC | $42.64 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $37.16 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| ADVANCE Normalized: advance |
Device | Cook Medical LLC | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| TRYVIO Normalized: tryvio |
Drug | IDORSIA PHARMACEUTICALS US INC | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| TORCON NB Normalized: torcon nb |
Device | Cook Medical LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| Altius Normalized: altius |
Device | Neuros Medical, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| COOK CELECT Normalized: cook celect |
Device | Cook Medical LLC | $10.93 | 1 | 2025 |
Source payment records
|
|||||
| NESTER Normalized: nester |
Device | Cook Medical LLC | $8.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 254 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 185 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 207 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
207 | 44 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
254 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
207 | 44 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
185 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
254 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Xarelto | Rivaroxaban | 293 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 275 | 79 |
| Eliquis | Apixaban | 254 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 251 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 75 |
| Jardiance | Empagliflozin | 207 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 69 |
| Furosemide | Furosemide | 186 | 52 |
| Entresto | Sacubitril/Valsartan | 185 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 46 |
| Carvedilol | Carvedilol | 121 | 24 |
| Repatha Sureclick | Evolocumab | 112 | 26 |
| Losartan Potassium | Losartan Potassium | 97 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 25 |
| Lisinopril | Lisinopril | 71 | 23 |
| Repatha Pushtronex | Evolocumab | 70 | 20 |
| Flecainide Acetate | Flecainide Acetate | 69 | 16 |
| Chlorthalidone | Chlorthalidone | 64 | 22 |
| Vascepa | Icosapent Ethyl | 60 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 13 |
| Brilinta | Ticagrelor | 38 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Ramipril | Ramipril | 36 | 14 |
| Sotalol | Sotalol Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Diazepam | Diazepam | 19 | 19 |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Prednisone | Prednisone | 12 | 12 |
| Simvastatin | Simvastatin | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $73,137.19 · 150 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ADVANCE, ANGIOVAC, AURYON LASER SYSTEM 100-120 VAC, AZURE XT DR MRI SURESCAN, Altius, Assure WCD, Aventus, Barostim Neo System, CAMZYOS, CGuard Prime Carotid Stent System, COOK, COOK CELECT, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, ENDOCROSS Device, ENTRESTO, FLOWTRIEVER CATHETER, S, GORE CARDIOFORM Septal Occluder, ICAST COVERED STENT SYSTEM, 6MMX22MMX120CM, JARDIANCE, Kerendia, LEQVIO, LIMFLOW SYSTEM, MYNX CONTROL VENOUS, NESTER, REPATHA, ROSEN, RotarexS 6 F x 135 cm, SYMPLICITY G3, TORCON NB, TORNADO, TRYVIO, Torus Stent Graft System, VERQUVO, VYNDAQEL, Varithena Administration Pack, VenaCure 1470 Pro, ZILVER PTX, ZILVER VENA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error